Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies - PubMed (original) (raw)
. 2000 Sep 12;55(5):713-5.
doi: 10.1212/wnl.55.5.713.
Affiliations
- PMID: 10980743
- DOI: 10.1212/wnl.55.5.713
Free article
Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies
I Rojas et al. Neurology. 2000.
Free article
Abstract
The outcome of 34 women with anti-Yo-associated paraneoplastic cerebellar degeneration was reviewed. Three patients had not developed cancer after more than 4 years of follow-up. The only independent predictor for survival was the type of associated tumor (risk ratio, 1.79; 95% CI, 1.02 to 3.12). Median survival was 100 months for patients with breast cancer and 22 for those with gynecologic cancer. Although paraneoplastic cerebellar degeneration leads to the diagnosis of cancer in 63% of the patients, cancer progression was the cause of death in 52%.
Similar articles
- Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients.
Shams'ili S, Grefkens J, de Leeuw B, van den Bent M, Hooijkaas H, van der Holt B, Vecht C, Sillevis Smitt P. Shams'ili S, et al. Brain. 2003 Jun;126(Pt 6):1409-18. doi: 10.1093/brain/awg133. Brain. 2003. PMID: 12764061 - Paraneoplastic cerebellar degeneration: Yo-expressing tumor revealed after a 5-year follow-up with FDG-PET.
Mathew RM, Cohen AB, Galetta SL, Alavi A, Dalmau J. Mathew RM, et al. J Neurol Sci. 2006 Dec 1;250(1-2):153-5. doi: 10.1016/j.jns.2006.06.029. Epub 2006 Oct 2. J Neurol Sci. 2006. PMID: 17011583 - Anti-Yo mediated paraneoplastic cerebellar degeneration in the context of breast cancer: a case report and literature review.
Key RG, Root JC. Key RG, et al. Psychooncology. 2013 Sep;22(9):2152-5. doi: 10.1002/pon.3270. Epub 2013 Apr 14. Psychooncology. 2013. PMID: 23585287 Review.
Cited by
- Immunological Bases of Paraneoplastic Cerebellar Degeneration and Therapeutic Implications.
Yshii L, Bost C, Liblau R. Yshii L, et al. Front Immunol. 2020 Jun 2;11:991. doi: 10.3389/fimmu.2020.00991. eCollection 2020. Front Immunol. 2020. PMID: 32655545 Free PMC article. Review. - Paraneoplastic cerebellar degeneration with anti-Yo antibodies and an associated submandibular gland tumor: a case report.
Imai T, Shinohara K, Uchino K, Okuma H, Maki F, Hiruma K, Ariizumi Y, Yamano Y. Imai T, et al. BMC Neurol. 2022 May 2;22(1):165. doi: 10.1186/s12883-022-02684-4. BMC Neurol. 2022. PMID: 35501715 Free PMC article. - Neuronal autoantigens--pathogenesis, associated disorders and antibody testing.
Lancaster E, Dalmau J. Lancaster E, et al. Nat Rev Neurol. 2012 Jun 19;8(7):380-90. doi: 10.1038/nrneurol.2012.99. Nat Rev Neurol. 2012. PMID: 22710628 Free PMC article. Review. - Paraneoplastic neurological syndromes: clinical presentations and management.
Devine MF, Kothapalli N, Elkhooly M, Dubey D. Devine MF, et al. Ther Adv Neurol Disord. 2021 Feb 1;14:1756286420985323. doi: 10.1177/1756286420985323. eCollection 2021. Ther Adv Neurol Disord. 2021. PMID: 33796141 Free PMC article. Review. - Immunomodulatory treatment trial for paraneoplastic neurological disorders.
Vernino S, O'Neill BP, Marks RS, O'Fallon JR, Kimmel DW. Vernino S, et al. Neuro Oncol. 2004 Jan;6(1):55-62. doi: 10.1215/S1152851703000395. Neuro Oncol. 2004. PMID: 14769141 Free PMC article. Clinical Trial.